Literature DB >> 9050920

Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism.

F Farnebo1, B T Teh, C Dotzenrath, W S Wassif, A Svensson, I White, R Betz, P Goretzki, K Sandelin, L O Farnebo, C Larsson.   

Abstract

Various genetic loci harboring oncogenes, tumor suppressor genes, and genes for calcium receptors have been implicated in the development of parathyroid tumors. We have carried out loss of heterozygosity (LOH) studies in chromosomes 1p, 1q, 3q, 6q, 11q, 13q, 15q, and X in a total of 89 benign parathyroid tumors. Of these, 28 were sporadic parathyroid adenomas from patients with no family history of the disease, 41 were secondary parathyroid tumors, 5 were from patients with a history of previous irradiation to the neck, 12 were from patients with a family history of hyperparathyroidism, and 3 were parathyroid tumors related to multiple endocrine neoplasia type 1 (MEN1). In addition, we determined the chromosomal localization of a second putative calcium-sensing receptor, CaS, for inclusion in the LOH studies. Based on analysis of somatic cell hybrids and fluorescent in situ hybridization to metaphase chromsomes, the gene for CaS was mapped to chromosomal region 2q21-q22. The following results were obtained from the LOH studies: (1) out of the 24 tumors that showed LOH, only 4 had more than one chromosomal region involved, (2) in the tumors from uremic patients, LOH of chromosome 3q was detected in a subset of the tumors, (3) LOH of the MEN1 region at 11q13 was the most common abnormality found in both MEN1-related and sporadic parathyroid tumours but was not a feature of the other forms of parathyroid tumors, (4) LOH in 1p and 6q was not as frequent as previously reported, and (5) tumor suppressor genes in 1q and X might have played a role, particularly on the X chromosome, in the case of familial parathyroid adenomas. We therefore conclude that the tumorigenesis of familial, sporadic, and uremic hyperparathyroidism involves different genetic triggers in a non-progressive pattern.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050920     DOI: 10.1007/s004390050369

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  12 in total

1.  Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism.

Authors:  Viive M Howell; John W Cardinal; Anne-Louise Richardson; Oliver Gimm; Bruce G Robinson; Deborah J Marsh
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

2.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

3.  HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.

Authors:  V M Howell; C J Haven; K Kahnoski; S K Khoo; D Petillo; J Chen; G J Fleuren; B G Robinson; L W Delbridge; J Philips; A E Nelson; U Krause; K Hammje; H Dralle; C Hoang-Vu; O Gimm; D J Marsh; H Morreau; B T Teh
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

4.  Increased incidence of neoplasia in chronic renal failure (20-year experience).

Authors:  Kuddusi Cengiz
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 5.  Molecular genetics of parathyroid disease.

Authors:  Gunnar Westin; Peyman Björklund; Göran Akerström
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

6.  Localization of tumor suppressor activity important in nonsmall cell lung carcinoma on chromosome 11q.

Authors:  Y Murakami; T Nobukuni; K Tamura; T Maruyama; T Sekiya; Y Arai; H Gomyou; A Tanigami; M Ohki; D Cabin; P Frischmeyer; P Hunt; R H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism.

Authors:  Trisha Dwight; Anne E Nelson; George Theodosopoulos; Anne Louise Richardson; Diana L Learoyd; Jeanette Philips; Leigh Delbridge; Jan Zedenius; Bin T Teh; Catharina Larsson; Deborah J Marsh; Bruce G Robinson
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

8.  Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Grzegorz Piecha; Jerzy Chudek; Andrzej Więcek
Journal:  Int J Endocrinol       Date:  2011-01-17       Impact factor: 3.257

9.  Identification of somatic mutations of the MEN1 gene in sporadic endocrine tumours.

Authors:  L Bergman; C Boothroyd; J Palmer; S Grimmond; M Walters; B Teh; J Shepherd; L Hartley; N Hayward
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

10.  Recurrent ZFX mutations in human sporadic parathyroid adenomas.

Authors:  Chen-Pang Soong; Andrew Arnold
Journal:  Oncoscience       Date:  2014-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.